CatalystMarker
← board

MDWD

MediWound Ltddistress 1/10 · well-funded / low risk
$14.370%today-32% from 52w high
mediwound.com121 employeesFounded 2000Yavne, IsraelBiotechnology
Lead: Venus Leg Ulcers
Revenue
pre-revenue
Liquidity
$53M
Runway
3.3 yrs
Shares 1y
0%

Price & events

-17.9% over 6M
$13.73$16.07$18.42Jan 26Apr 26Jul 26451krating: HC Wainwright & Co.: Buy (2026-05-28)rating: Oppenheimer: Outperform (2026-05-28)
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-1.6%
1W
+2.1%
1M
-13.7%
3M
-18.8%
6M
-31.6%
1Y
-26.9%
2Y
-47.4%
5Y
-45.5%
All

Overview

Market Cap
$184.44M
Volume
2.35K
52 Week Range
$13.73 – $21.00
Total Shares
12.84M
Float Shares
8.83M
Short %
14.50%
% Held by Insiders
15.86%
% Held by Institutions
58.46%
RVOL
0.03x
Beta
0.14

Pipeline stages · 1 programs

EscharEx (EX-03)
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved
next 2026-12

Pipeline · 2 trials · 2 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-12
Estimated 50%
readout ~2027-02-14
Phase 3EscharEx (EX-03)Venous Leg Ulcer (VLU)recruiting
2027-12-30
Estimated 50%
readout ~2028-02-13
Phase 2EscharEx (EX-03)Venus Leg Ulcersnot yet recruiting

Catalyst news & presentations · 1

Approved drugs (1)

  • NEXOBRIDANACAULASE-BCDB2022 · Prescription

Capital structure — dilution & financing

Shares out: 12,835,148 · 1 offerings/1y · 0 PIPEs
  • 2025-09-30424B5offering
  • 2025-03-28424B3offering
  • 2025-03-27EFFECTshelf_effective
  • 2025-03-19F-3shelf_registration
  • 2024-11-14SC 13G/Astrategic_stake
  • 2024-10-23SC 13G/Astrategic_stake
  • 2024-10-01SC 13Gstrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-05-28HC Wainwright & Co.Buy
  • 2026-05-28OppenheimerOutperform
  • 2025-11-21HC Wainwright & Co.Buy
  • 2025-05-22HC Wainwright & Co.Buy
  • 2025-03-20HC Wainwright & Co.Buy
  • 2025-02-28Craig-HallumBuy

Competitors — Venus Leg Ulcers

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.